Navigation Links
Off-label drug use common, but patients may not know they're taking them, Mayo finds
Date:8/6/2012

Aug. 6, 2012

ROCHESTER, Minn. -- Many people have probably heard of off-label drug use, but they may not know when that applies to prescriptions they are taking, a Mayo Clinic analysis found. Off-label drug use occurs when a physician prescribes medication to treat a condition before that use has been approved by the Food and Drug Administration. In a newly published article in Mayo Clinic Proceedings, researchers pose and answer 10 questions about off-label drug use.

"Since the Food and Drug Administration does not regulate the practice of medicine, off-label drug use has become very common," says lead author Christopher Wittich, M.D., internal medicine physician at Mayo Clinic. "Health care providers and patients should educate themselves about off-label drugs to weigh the risks and benefits before a physician prescribes one or a patient takes one."

Some highlights from the article:

  • Off-label drug use is common. Within a group of commonly used medications, roughly 1 in 5 prescriptions were for an off-label use, a 2006 report found. Another study found that about 79 percent of children discharged from pediatric hospitals were taking at least one off-label medication.
  • Patients may not know when drugs they have been prescribed are being used off-label. No court decision has required that physicians must disclose, through informed consent, the off-label use of a drug, the authors say. The FDA makes clear that it doesn't regulate the practice of medicine and that the federal Food, Drug, and Cosmetic Act of 1938 doesn't make physicians liable for off-label drug use, they note.
  • Off-label drug use can become the predominant treatment for a condition. For example, some antidepressants are not approved by the FDA as a treatment for neuropathic pain, yet some drugs in this class are considered a first-line treatment option.
  • Examples of widely practiced off-label drug use include morphine, used extensively to treat pain in hospitalized pediatric patients. Many inhaled bronchodilators, antimicrobials, anticonvulsants, and proton pump inhibitors also are used in children without formal FDA approval.
  • Obtaining new FDA approval for a medication can be costly and time-consuming. To add additional indications for an already approved medication requires a supplemental drug application; if eventually approved, revenue from it may not offset the expense and effort for obtaining approval.
  • Generic medications may not have the requisite funding resources needed to pursue FDA-approval studies. For these financial reasons, drug proprietors may never seek FDA approval for a new drug indication.
  • Pharmaceutical manufacturers are not allowed to promote off-label uses of medications. However, they can respond to unsolicited questions from health care providers and distribute peer-reviewed publications about off-label use. Just this year, GlaxoSmithKline agreed to pay a record $3 billion to settle a Justice Department case involving alleged off-label drug use marketing, and Merck Sharp & Dohme was fined $322 million over its alleged promotion of the painkiller Vioxx for an off-label use.


'/>"/>

Contact: Nick Hanson
newsbureau@mayo.edu
507-284-5005
Mayo Clinic
Source:Eurekalert

Related medicine news :

1. Off-Label Drug Use Appears Common
2. Reducing off-label use of antipsychotic medications may save money
3. Texting in College Classrooms Common, Distracting
4. Higher-spending hospitals have fewer deaths for emergency patients
5. Researchers uncover a viable way for colorectal cancer patients to overcome drug resistance
6. Vaccine yielded encouraging long-term survival rates in certain patients with NSCLC
7. Study finds doctors have exaggerated fears when starting patients on insulin
8. Diagnostic Scans Tied to Radiation Risk for Gastro Patients
9. Predictors identified for rehospitalization among post-acute stroke patients
10. Pulse pressure elevation could presage cerebrovascular disease in Alzheimers patients
11. Breast cancer patients suffer treatment-related side effects long after completing care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/16/2017)... Belleville, IL (PRWEB) , ... January 16, 2017 ... ... molded seating manufacturer Prairie Seating. Prairie’s award-winning Reflection® brand of custom seating systems ... detail. The acquisition provides Permobil with a platform for innovation and growth in ...
(Date:1/16/2017)... ... January 16, 2017 , ... Board-certified oculoplastic surgeon ... , the official journal of The American Society for Aesthetic Plastic Surgery, in ... procedure is designed to correct drooping, retracted lower eyelids, which usually result from ...
(Date:1/16/2017)... ... , ... NexTec Group has been selected as a member of the Bob ... in the field of midmarket financial software. , Members of the VAR Stars were ... not based on revenue and those firms chosen represent a wide range of size ...
(Date:1/15/2017)... Viejo, California (PRWEB) , ... January 15, 2017 , ... ... a stylistic slideshow with complete customization and ease," said Christina Austin - CEO of ... of controls so that users can edit the style and animation of their slideshows. ...
(Date:1/14/2017)... ... January 14, 2017 , ... Healthy living ... line of activated charcoal products. With more and more people opting to go ... according to how they cater to specific needs. , Moody Zook focused particularly ...
Breaking Medicine News(10 mins):
(Date:1/16/2017)... -- CBDRx, the world,s premiere nutraceutical hemp company, is ... extract to Veteran,s groups across the country. ... to Veteran,s groups across the United States.  Passion is ... world and through their passion, CBDRx honors our Veterans ... hemp extract available. ...
(Date:1/15/2017)... DUBLIN , January 16, 2017 ... produits innovants à base de collagène pour la régénération de ... au poste de directeur général avec effet immédiat. ... Bill est ... qui a occupé plusieurs postes de gestion générale et de ...
(Date:1/14/2017)...  Johnson & Weaver, LLP announces that a class action ... Holdings, Inc. (NYSE: ZBH )  securities during the ... "Class Period"). Zimmer Biomet provides musculoskeletal healthcare products ... such as knee and hip reconstructive products. ... According to the complaint, ...
Breaking Medicine Technology: